Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
Lydia Scarfò(IRCCS Ospedale San Raffaele), Paolo Ghia(Vita-Salute San Raffaele University), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Laurenti(Sapienza University of Rome), Marta Coscia(University of Turin), Rosaria Sancetta(Ospedale dell' Angelo), Luana Schiattone(IRCCS Ospedale San Raffaele), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Colia(IRCCS Ospedale San Raffaele), Paolo Rivela(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Eleonora Perotta(IRCCS Ospedale San Raffaele), Andrea Ferrario(University of Applied Sciences and Arts of Southern Switzerland), Silvia Heltai(IRCCS Ospedale San Raffaele), Elisabetta Albi(University of Perugia), Marzia Varettoni(Policlinico San Matteo Fondazione), Pamela Ranghetti(IRCCS Ospedale San Raffaele), Eloise Scarano(IRCCS Ospedale San Raffaele), Antonella Capasso(IRCCS Ospedale San Raffaele), Marina Motta(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia)
Cited by 10
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890